Carbapenem susceptibility testing errors using three automated systems, disk diffusion, etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4707-4711

  Markelz, Ana Elizabeth ^a   Mende, Katrin ^a,c   Murray, Clinton K ^a,b   Yu, Xin ^a   Zera, Wendy C ^a,c   Hospenthal, Duane R ^a,b   Beckius, Miriam L ^a   Calvano, Tatjana ^a   Akers, Kevin S ^a,b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; DISK DIFFUSION; EPSILOMETER TEST; ERROR; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 80052837917     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00112-11     Document Type: Article

References (24)

1. Akers, K. S., et al. 2010. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J. Clin. Microbiol. 48:1132-1138.
2. Castanheira, M., R. N. Jones, and D. M. Livermore. 2009. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn. Microbiol. Infect. Dis. 63:426-433.
3. Cockerill, F. R., et al. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Ellington, M. J., J. Kistler, D. M. Livermore, and N. Woodford. 2007. Multiplex PCR for rapid detection of genes encoding acquired metallo-betalactamases. J. Antimicrob. Chemother. 59:321-322.
5. Esterly, J. S., C. Qi, M. Malczynski, and M. H. Scheetz. 2010. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and blaOXA gene status. Pharmacotherapy 30:354-360.
6. European Committee on Antimicrobial Susceptibility Testing. 5 January 2011. Breakpoint tables for interpretation of MICs and zone diameters, version 1.3. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Disk-test- documents/EUCAST-breakpoints-v1.3-pdf.pdf.
7. Hope, R., T. Pllana, M. Warner, and D. M. Livermore. 2010. Proposed disc zone breakpoints for doripenem for use with the BSAC disc susceptibility testing method. J. Antimicrob. Chemother. 65:1547-1548.
8. Hsieh, W. S., L. L. Sung, K. C. Tsai, and H. T. Ho. 2009. Evaluation of the VITEK 2 cards for identification and antimicrobial susceptibility testing of non-glucose-fermenting Gram-negative bacilli. APMIS 117:241-247.
9. Hujer, K. M., et al. 2006. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 50:4114-4123.
10. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
11. Jorgensen, J. H., and M. J. Ferraro. 2009. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin. Infect. Dis. 49:1749-1755.
12. Joyanes, P., M. del Carmen Conejo, L. Martínez-Martínez, and E. J. Perea. 2001. Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples. J. Clin. Microbiol. 39:3247-3253.
13. Karlowsky, J. A., et al. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688.
14. Keen, E. F., III, et al. 2010. Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center. Infect. Control Hosp. Epidemiol. 31:728-732.
15. Kulah, C., et al. 2009. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAway. BMC Infect. Dis. 9:30.
16. Menozzi, M. G., et al. 2006. Two-center collaborative evaluation of performance of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of gram-negative bacteria. J. Clin. Microbiol. 44:4085-4094.
17. Mera, R. M., L. A. Miller, H. Amrine-Madsen, and D. F. Sahm. 2010. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb. Drug Resist. 16:209-215.
18. Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2007. Doribax (doripenem for injection). Package insert. Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ. http://doribax.com/shared/pi/doribax.pdf.
19. Peleg, A. Y., H. Seifert, and D. L. Paterson. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
20. Rasheed, J. K., et al. 2008. Detection of the Klebsiella pneumoniae carbapenemase type 2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J. Clin. Microbiol. 46:2066-2069. (Pubitemid 351831844)
21. Taherikalani, M., et al. 2008. Emergence of multi and pan-drug resistance Acinetobacter baumannii carrying blaOXA-type carbapenemase genes among burn patients in Tehran, Iran. Saudi Med. J. 29:623-624.
22. OXA-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 44:2974-2976.
23. U.S. Food and Drug Administration. 2010. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA. U.S. Food and Drug Administration, Rockville, MD.
24. Woodford, N., et al. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 27:351-353.